We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SERF VT Ablation Early Feasibility Study (EFS) (SERF VT EFS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03628534
Recruitment Status : Completed
First Posted : August 14, 2018
Last Update Posted : August 10, 2022
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Thermedical, Inc.

Tracking Information
First Submitted Date  ICMJE July 26, 2018
First Posted Date  ICMJE August 14, 2018
Last Update Posted Date August 10, 2022
Actual Study Start Date  ICMJE November 1, 2018
Actual Primary Completion Date June 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 20, 2022)
  • EFFICACY: Non-inducibility of the targeted clinical VT at end of ablation procedure. [ Time Frame: By the end of the procedure ]
    Completion of intended ablation during treatment setting as measured by non-inducibility of the targeted clinical VT (acute procedural success).
  • SAFETY: SAEs that are probably or definitely device related within 30 days [ Time Frame: within 30 days ]
Original Primary Outcome Measures  ICMJE
 (submitted: August 8, 2018)
  • EFFICACY: Non-inducibility of the targeted clinical VT at end of ablation procedure. [ Time Frame: By the end of the procedure ]
    Completion of intended ablation during treatment setting as measured by non-inducibility of the targeted clinical VT (acute procedural success).
  • SAFETY: Serious adverse events that are probably or definitely device related related [ Time Frame: within 30 days ]
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE SERF VT Ablation Early Feasibility Study (EFS)
Official Title  ICMJE Saline Enhanced Radiofrequency (SERF) VT Ablation Early Feasibility Study (EFS)
Brief Summary This is an early feasibility, non-randomized, open-label, single group, interventional study to be conducted in up to 20 US subjects to evaluate the technical feasibility of the Durablate Catheter and Thermedical Ablation System to eliminate or control sustained, monomorphic ventricular tachycardia (VT) in patients with VT refractory to drug and conventional catheter ablation with acceptable procedural safety.
Detailed Description The purpose of this study is to gather information on the technical feasiability and safety of a needle ablation catheter called the Durablate™ Saline Enhanced Radiofrequency (SERF) catheter. This catheter is being studied to treat ventricular tachycardia (VT) in patients who have already been treated with medicine, have an Implantable Cardioverter Defibrillator (ICD) and had an ablation procedure to treat their VT but continue to experience VT despite these treatments. A VT ablation procedure is done by finding the abnormal heart tissue that's causing the VT and applying energy with the tip of an ablation catheter to the area to create a scar or destroy the tissue that causes the VT. The SERF catheter being used in this study uses a needle to deliver heated saline (salt water) and radiofrequency energy deeper into the heart tissue that is causing the VT than a standard ablation catheter.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Thermedical SERF Ablation System and Durablate Catheter
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Ventricular Tachycardia
  • Arrythmia
  • Heart Diseases
  • Cardiovascular Diseases
Intervention  ICMJE Device: Saline Enhanced Radiofrequency (SERF) ablation
Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
Other Name: Durablate Catheter and Thermedical Ablation System
Study Arms  ICMJE Experimental: single arm
Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
Intervention: Device: Saline Enhanced Radiofrequency (SERF) ablation
Publications * Packer DL, Wilber DJ, Kapa S, Dyrda K, Nault I, Killu AM, Kanagasundram A, Richardson T, Stevenson W, Verma A, Curley M; SERF Investigators. Ablation of Refractory Ventricular Tachycardia Using Intramyocardial Needle Delivered Heated Saline-Enhanced Radiofrequency Energy: A First-in-Man Feasibility Trial. Circ Arrhythm Electrophysiol. 2022 Aug;15(8):e010347. doi: 10.1161/CIRCEP.121.010347. Epub 2022 Jul 1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 20, 2022)
16
Original Estimated Enrollment  ICMJE
 (submitted: August 8, 2018)
20
Actual Study Completion Date  ICMJE July 31, 2022
Actual Primary Completion Date June 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject has sustained, monomorphic VT
  2. Subject has recurrent, symptomatic VT
  3. Subject has drug refractory or drug intolerant sustained VT following use of at least one Class III antiarrhythmic as demonstrated by a recurrent arrhythmia and is not a suitable candidate per the investigator's expert opinion for ongoing or alternative drug therapy
  4. ECG and/or ICD evidence of a spontaneous VT recurrence within the prior 6 months that is suspected to be the same VT as initially targeted in a prior ablation
  5. Subject has minimum 3-month ICD interrogation history available for evaluation
  6. Subject has LVEF > 20%, confirmed by echo or comparable technique during baseline evaluation
  7. Subject is at least 18 years old
  8. Subject has signed the informed consent, and is willing and able to participate in all study procedures and follow up requirements

EXCLUSION CRITERIA:

  1. Subjects with VT of idiopathic origin
  2. Subjects with VT with ECG or MRI/CT findings suggestive of right ventricular free wall origin
  3. Subjects with VTs of septal origin require special care to minimize the risk of heart block, particularly within 2 cm of the AV node/proximal conduction system; Subjects requiring ablation at such locations should only be included when the arrhythmia itself is life-threatening or otherwise sufficiently severe to justify the risk
  4. Subject with myocardial infarction (MI) or unstable angina within previous 60 days
  5. Subject with cardiac surgery or percutaneous coronary intervention (PCI) within previous 60 days
  6. Subject with class IV (NYHA) heart failure
  7. Subject with prosthetic cardiac valve(s), severe aortic stenosis or flail mitral valve
  8. Subject with left ventricular assist device planned or required for the procedure
  9. Subjects with co-morbidities such that they have less than 1-year life expectancy
  10. Subject with evidence of intracardiac and/or laminated thrombus (in the left atrium including left atrial appendage or the left ventricle) evident by cardiac CT or transesophageal echo (TEE) and transthoracic echo (TTE) (with contrast if indicated) within 48 hours prior to ablation procedure
  11. Subject with thrombocytopenia or other coagulopathy
  12. Women who are or may potentially be pregnant (must be post-menopausal or have a negative pregnancy test)
  13. Subject with other acute illness or active systemic infection (unrelated to VT or its origin)
  14. Significant congenital heart disease or cardiac anomaly
  15. Allergy or contraindications to the medications/agents used during a standard ablation/EP intervention.
  16. Subject concurrently enrolled in any other investigational drug or device study that the investigator deems would interfere with study results
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries Canada
 
Administrative Information
NCT Number  ICMJE NCT03628534
Other Study ID Numbers  ICMJE CP-100
1R44HL132746-01A1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Thermedical, Inc.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Thermedical, Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE National Heart, Lung, and Blood Institute (NHLBI)
Investigators  ICMJE
Principal Investigator: Douglas Packer, MD Mayo Clinic
PRS Account Thermedical, Inc.
Verification Date August 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP